Who We Are
We are a privately held medical device company developing a novel, rapid-acting brain stimulation technology designed to treat people suffering from major depressive disorder (MDD) who have not responded to existing treatments.
Our Mission
RESTORING MENTAL HEALTH.
Depression is caused by identifiable changes in brain networks.
We can restore healthy neural activity and relieve symptoms of depression.
What We Do
Breakthrough technology. Advanced imaging, individualized targeting, and novel stimulation patterns yield a new approach to personalized neurostimulation for people with treatment-resistant depression.
Leadership
Brett Wingeier
PhD
Co-Founder and Chief Technology Officer
Previously CEO and co-founder of Halo Neuroscience. 20 years of neuromodulation industry experience. NeuroPace and ATI alumnus, former principal engineer and clinical scientist. Registered patent agent and prolific inventor with 60+ US patents.
Tammy Morton
Vice President of Clinical Affairs
25 years’ experience in planning and executing clinical trials to support approval of class II and class III medical devices in a variety of therapeutic areas at both startups and large companies. Previously VP of Clinical Affairs at Radial Medical and Halo Neuroscience; in-depth clinical affairs experience at Gynesonics, Abbott Vascular and Bailer Research.
Susan Noriega
Vice President of Regulatory Affairs
30+ years’ regulatory affairs, quality, and clinical experience in the medical device industry with an emphasis on the development of comprehensive global regulatory strategies. Consulted with over 80 medical device companies and held leadership positions at AliveCor, SI-BONE, FARAPULSE, Roche Diagnostics, ZOLL Medical Corporation, and Revascular Therapeutics (BSC).
Leslie Stephens
Vice President of Reimbursement
20+ years’ experience in market access and reimbursement, marketing, and market development in the medical device industry. Previously EVP of Marketing at Elixir Medical and VP of Market Access at Heartflow; held multiple leadership positions at Abbott Vascular in Market Access and Marketing.
Investors
Heath Lukatch
PhD
Chairman of the Board – Magnus Medical
Founder and Managing Partner – Red Tree Venture Capital
Previously Partner, Managing Director, and Life Sciences Investment Team Leader in TPG’s Biotech, Growth and RISE platforms; co-founder and Partner at Novo Ventures’ San Francisco office; Managing Director at Piper Jaffray Ventures; co-founder and CEO of AutoMate Scientific. Led multiple investments with successful exits, including Amira, AnaptysBio, Cianna Medical, Engage Therapeutics, Elevation Pharma, Flexion, FoldRx, Spinifex and Vaxcyte. Currently chairman of publicly traded companies Inogen and Satsuma Pharmaceuticals. McKinsey alumnus with PhD in neuroscience from Stanford.
Andrew Firlik
MD
Co-Founder and Managing Partner – JAZZ Venture Partners
Deep experience in venture capital investment, company building, technology development, and neurosurgery. Previous partner at Flare Capital Partners and principal at Canaan Partners; founder and key inventor of Northstar Neuroscience (IPO in 2006, subsequently acquired by St. Jude Medical); was chairman of IntElect Medical (acquired by Boston Scientific). Led investments with successful exit and held board seats at BridgePoint Medical, Explorys, Eyefluence, Visiogen, and more. Board-certified neurosurgeon with over 50 medical articles and numerous patents.